Correlation Between DEXIA SA and Bristol-Myers Squibb

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both DEXIA SA and Bristol-Myers Squibb at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining DEXIA SA and Bristol-Myers Squibb into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between DEXIA SA BELGIUM and Bristol Myers Squibb, you can compare the effects of market volatilities on DEXIA SA and Bristol-Myers Squibb and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in DEXIA SA with a short position of Bristol-Myers Squibb. Check out your portfolio center. Please also check ongoing floating volatility patterns of DEXIA SA and Bristol-Myers Squibb.

Diversification Opportunities for DEXIA SA and Bristol-Myers Squibb

0.0
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between DEXIA and Bristol-Myers is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding DEXIA SA BELGIUM and Bristol Myers Squibb in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Bristol Myers Squibb and DEXIA SA is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on DEXIA SA BELGIUM are associated (or correlated) with Bristol-Myers Squibb. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Bristol Myers Squibb has no effect on the direction of DEXIA SA i.e., DEXIA SA and Bristol-Myers Squibb go up and down completely randomly.

Pair Corralation between DEXIA SA and Bristol-Myers Squibb

If you would invest (100.00) in Bristol Myers Squibb on January 26, 2024 and sell it today you would earn a total of  100.00  from holding Bristol Myers Squibb or generate -100.0% return on investment over 90 days.
Time Period3 Months [change]
DirectionFlat 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

DEXIA SA BELGIUM  vs.  Bristol Myers Squibb

 Performance 
       Timeline  
DEXIA SA BELGIUM 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days DEXIA SA BELGIUM has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable technical and fundamental indicators, DEXIA SA is not utilizing all of its potentials. The latest stock price disturbance, may contribute to mid-run losses for the stockholders.
Bristol Myers Squibb 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Bristol Myers Squibb has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable primary indicators, Bristol-Myers Squibb is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors.

DEXIA SA and Bristol-Myers Squibb Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with DEXIA SA and Bristol-Myers Squibb

The main advantage of trading using opposite DEXIA SA and Bristol-Myers Squibb positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if DEXIA SA position performs unexpectedly, Bristol-Myers Squibb can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol-Myers Squibb will offset losses from the drop in Bristol-Myers Squibb's long position.
The idea behind DEXIA SA BELGIUM and Bristol Myers Squibb pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.

Other Complementary Tools

Content Syndication
Quickly integrate customizable finance content to your own investment portal
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Transaction History
View history of all your transactions and understand their impact on performance
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance